Developer docs
API playgroundTry for free, no card

Search company profiles

CB1 Medical

Full company profile

uuid0043kuc

Namestring
CB1 Medical
Websiteurl
cb1medical.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

CB1 Medical is a United Kingdom-based medical entity incorporated in 2023 and headquartered in Leicester, operating with a 9-person team. The brand name references the CB1 cannabinoid receptor, suggesting thematic alignment with cannabinoid or endocannabinoid-system-related medical activity, though the specific therapeutic focus, product portfolio, and clinical pipeline cannot be confirmed from available sources.

At the time of data capture, the company's public website (cb1medical.com) was presenting a loading/verification interstitial rather than substantive company content. As a result, no products, services, underlying technology, clinical assets, regulatory filings, certifications, partnerships, customer segments, pricing structure, distribution channels, or revenue model could be verified. The input also lacks disclosed funding rounds, management team details, office locations beyond the Leicester headquarters, social profiles, patents, trademarks, or M&A history.

On that evidentiary basis, CB1 Medical should be regarded as an early-stage, sub-scale UK medical entity whose commercial direction, technological stack, and go-to-market mechanics are presently unobservable. Any further diligence — including confirmation of whether the company operates in cannabinoid therapeutics, medical devices, digital health, or a related vertical — requires primary-source verification beyond what the current loading-state website and empty data fields provide.

Short descriptiontext

CB1 Medical is a Leicester, UK-based medical entity founded in 2023 with 9 employees. Its specific products, technology, and customer base are unverifiable from current sources, as the public website displays a non-functional loading page.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
Markets served

Serves global market

Keyword5 values
medical services, healthcare provider, medical practice, clinical services, patient care
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Medical Practice
Social media profiles1 record
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

No core offering could be determined from the available source material. The CB1 Medical website (cb1medical.com) only displays a loading/verification page and contains no product, service, or business description.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers8 records
TypeDirect peer
Description

Clinical-stage French biotech specifically developing CB1 receptor signaling-specific compounds (CB1-SSi) for metabolic and neurological disorders. The most directly comparable peer in terms of both target (CB1) and indication strategy.

TypeEmerging player
Description

Clinical-stage biotech developing cannabinoid receptor-modulating therapeutics for cancer, pain, and inflammation. Comparable as a small, endocannabinoid-pathway-focused developer.

TypeDirect peer
Description

US-based biotech developing endocannabinoid system-targeted therapeutics, historically focused on cannabinoid receptor pathways. Comparable as a small-cap, endocannabinoid-focused drug developer.

4Botanix Pharmaceuticals
TypeEmerging player
Description

Clinical-stage dermatology-focused cannabinoid therapeutics company developing synthetic CBD formulations (e.g., Sofpironium Bromide). Comparable as a small-cap cannabinoid therapeutics developer pursuing differentiated formulations.

5Ananda Developments
TypeEmerging player
Description

UK-listed, early-stage company developing cannabinoid-based medicines for chronic conditions including endometriosis and epilepsy. Comparable as a UK-based, early-stage cannabinoid therapeutics developer.

TypeEmerging player
Description

Pre-clinical/early-clinical stage cannabinoid pharmaceutical company focused on rare cannabinoid APIs and formulation technology. Comparable as a small-cap cannabinoid-based therapeutic developer.

TypeBroad incumbent
Description

Acquired GW Pharmaceuticals in 2021 and now markets Epidiolex (cannabidiol) and previously Sativex — the established incumbent in cannabinoid-based prescription medicines. Comparable as a benchmark for the regulatory and commercial path of cannabinoid therapeutics.

8Tilray Brands
TypeBroad incumbent
Description

Large diversified cannabis company with a pharmaceutical division working on cannabinoid-based medicines. Provides a broader industry benchmark rather than a direct preclinical R&D competitor.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights2 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CB1 Medical

Medical Practicecb1medical.com

CB1 Medical is a Leicester, UK-based medical entity founded in 2023 with 9 employees. Its specific products, technology, and customer base are unverifiable from current sources, as the public website displays a non-functional loading page.

What CB1 Medical does

CB1 Medical is a United Kingdom-based medical entity incorporated in 2023 and headquartered in Leicester, operating with a 9-person team. The brand name references the CB1 cannabinoid receptor, suggesting thematic alignment with cannabinoid or endocannabinoid-system-related medical activity, though the specific therapeutic focus, product portfolio, and clinical pipeline cannot be confirmed from available sources.

At the time of data capture, the company's public website (cb1medical.com) was presenting a loading/verification interstitial rather than substantive company content. As a result, no products, services, underlying technology, clinical assets, regulatory filings, certifications, partnerships, customer segments, pricing structure, distribution channels, or revenue model could be verified. The input also lacks disclosed funding rounds, management team details, office locations beyond the Leicester headquarters, social profiles, patents, trademarks, or M&A history.

On that evidentiary basis, CB1 Medical should be regarded as an early-stage, sub-scale UK medical entity whose commercial direction, technological stack, and go-to-market mechanics are presently unobservable. Any further diligence — including confirmation of whether the company operates in cannabinoid therapeutics, medical devices, digital health, or a related vertical — requires primary-source verification beyond what the current loading-state website and empty data fields provide.

CB1 Medical firmographics

Firmographics
Name
CB1 Medical
Website
https://cb1medical.com
Company type
Private
Headcount range
11–50 employees
Short description
CB1 Medical is a Leicester, UK-based medical entity founded in 2023 with 9 employees. Its specific products, technology, and customer base are unverifiable from current sources, as the public website displays a non-functional loading page.
Ownership category
akta.pro rank

CB1 Medical business model

Business model
GTM type
B2C
Offering type
Services

CB1 Medical product offering

Product offering

Core offering

No core offering could be determined from the available source material. The CB1 Medical website (cb1medical.com) only displays a loading/verification page and contains no product, service, or business description.

Differentiator

Problem solved

Functional benefit

Companies that use CB1 Medical

Customer profile

Ideal customer profiles1 record

CB1 Medical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

CB1 Medical partnerships and signals

Strategic signal

Recent moves1 record

CB1 Medical competitors and assessment

Company assessment

Direct peers

  • Aelis Farma: Clinical-stage French biotech specifically developing CB1 receptor signaling-specific compounds (CB1-SSi) for metabolic and neurological disorders. The most directly comparable peer in terms of both target (CB1) and indication strategy.
  • Corbus Pharmaceuticals: US-based biotech developing endocannabinoid system-targeted therapeutics, historically focused on cannabinoid receptor pathways. Comparable as a small-cap, endocannabinoid-focused drug developer.

Emerging players

  • Artelo Biosciences: Clinical-stage biotech developing cannabinoid receptor-modulating therapeutics for cancer, pain, and inflammation. Comparable as a small, endocannabinoid-pathway-focused developer.
  • Botanix Pharmaceuticals: Clinical-stage dermatology-focused cannabinoid therapeutics company developing synthetic CBD formulations (e.g., Sofpironium Bromide). Comparable as a small-cap cannabinoid therapeutics developer pursuing differentiated formulations.
  • Ananda Developments: UK-listed, early-stage company developing cannabinoid-based medicines for chronic conditions including endometriosis and epilepsy. Comparable as a UK-based, early-stage cannabinoid therapeutics developer.
  • InMed Pharmaceuticals: Pre-clinical/early-clinical stage cannabinoid pharmaceutical company focused on rare cannabinoid APIs and formulation technology. Comparable as a small-cap cannabinoid-based therapeutic developer.

Broad incumbents

  • Jazz Pharmaceuticals (GW Pharmaceuticals): Acquired GW Pharmaceuticals in 2021 and now markets Epidiolex (cannabidiol) and previously Sativex — the established incumbent in cannabinoid-based prescription medicines. Comparable as a benchmark for the regulatory and commercial path of cannabinoid therapeutics.
  • Tilray Brands: Large diversified cannabis company with a pharmaceutical division working on cannabinoid-based medicines. Provides a broader industry benchmark rather than a direct preclinical R&D competitor.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights2 records

Customer concentration

CB1 Medical social profiles

Digital presence

CB1 Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CB1 Medical leadership team

Management profile

Number of profiles

CB1 Medical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CB1 Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CB1 Medical

What does CB1 Medical do?

No core offering could be determined from the available source material. The CB1 Medical website (cb1medical.com) only displays a loading/verification page and contains no product, service, or business description.

When was CB1 Medical founded?

CB1 Medical was founded in -1. It employs 11 to 50 people.

Who are CB1 Medical's main competitors?

Direct peers on record are Aelis Farma and Corbus Pharmaceuticals. Emerging players are Artelo Biosciences, Botanix Pharmaceuticals, Ananda Developments and InMed Pharmaceuticals. Broad incumbents are Jazz Pharmaceuticals (GW Pharmaceuticals) and Tilray Brands.

Does CB1 Medical have an API?

No public API is recorded for CB1 Medical.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals